Makes Chai-1 and Chai-2, open-weight structure models used for antibody and binder design.
Chai Discovery, based in San Francisco, makes Chai-1 and Chai-2, open-weight structure prediction models used for antibody and binder design. Chai-1, released in 2024, matched AlphaFold 3 on many benchmarks with open weights for non-commercial use, and Chai-2, released in 2025, reported zero-shot de novo antibody hit rates far above earlier methods. OnCo links it to the Chai-1 and Chai-2 technology record. Whether high computational hit rates translate into antibodies that behave in patients is the open question. Chai-1 and Chai-2 have their own technology page.
Shares the tags ai, protein-design.
Shares the tags ai, protein-design.
Shares the tags ai, protein-design.
Shares the tags ai, protein-design.
Shares the tags ai, protein-design.
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico and the tag ai.
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico and the tag ai.
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico and the tag ai.
Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Chai Discovery's multi-modal structure prediction model; code and weights are released, with commercial use permitted under its terms.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/